<DOC>
	<DOCNO>NCT02632409</DOCNO>
	<brief_summary>The purpose study determine efficacy safety nivolumab versus placebo participant undergone radical surgery invasive urothelial cancer .</brief_summary>
	<brief_title>A Study Nivolumab , Compared Placebo , Patients With Bladder Upper Urinary Tract Cancer , Following Surgery Remove Cancer</brief_title>
	<detailed_description />
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Must invasive urothelial cancer high risk recurrence originate bladder , ureter , renal pelvis Must radical surgical resection ( e.g . radical cystectomy ) , perform within last 90 day Must disease free status determine image within 4 week dose Tumor tissue must provide biomarker analysis Patients receive prior neoadjuvant cisplatin chemotherapy must ineligible refuse cisplatinbased adjuvant chemotherapy Partial bladder kidney removal ( eg , partial cystectomy ) Secondary Treatment ( eg , adjuvant systemic chemotherapy bladder cancer ) follow surgical removal bladder cancer Subjects active , know suspected autoimmune disease Prior malignancy active within previous 3 year except locally curable cancer apparently cure Condition require systemic treatment either corticosteroid immunosuppressive medication within 14 day study drug administration Positive test hepatitis B virus surface antigen ( HBV Ag ) hepatitis C virus ribonucleic acid ( HCV antibody ) indicate acute chronic infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>